P2Y12 receptor inhibition augments cytotoxic effects of cisplatin in breast cancer

Sasmit Sarangi, Ambarish Pandey, Anne Laure Papa, Poulomi Sengupta, Jawahar Kopparam, Ushashi Dadwal, Sudipta Basu, Shiladitya Sengupta

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Expression of P2Y12 receptors has been documented in some cancer cell lines like C6 glioma, renal carcinoma and colon carcinoma. However, its direct role in altering response to chemotherapeutics has not been studied. In this study, we characterize the expression of P2Y12 receptor in breast cancer cell lines and evaluate its role in enhancing the cytotoxic effects of cisplatin. We observed a significant upregulation in P2Y12 expression in 4T1 breast cancer cell line with cisplatin treatment. Co-administration of P2Y12 inhibitor with cisplatin resulted in significantly higher cytotoxic response in 4T1 cancer cell line. This was mediated by HIF1α-dependent upregulation of cellular apoptotic pathways. These findings identify P2Y12 receptor as a potential target to enhance antitumor efficacy of chemotherapeutic agents like cisplatin.

Original languageEnglish (US)
Article number567
JournalMedical Oncology
Issue number2
StatePublished - Jun 2013


  • Breast cancer
  • Cisplatin
  • HIF1α
  • P2Y12 receptor

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'P2Y12 receptor inhibition augments cytotoxic effects of cisplatin in breast cancer'. Together they form a unique fingerprint.

Cite this